Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells define commitment to apoptosis

The imatinib paradigm in chronic myeloid leukemia (CML) established continuous BCR-ABL inhibition as a design principle for ABL tyrosine kinase inhibitors (TKIs). However, clinical responses seen in patients treated with the ABL TKI dasatinib despite its much shorter plasma half-life and the apparen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: O’Hare, Thomas, Eide, Christopher A., Agarwal, Anupriya, Adrian, Lauren T., Zabriskie, Matthew S., MacKenzie, Ryan J., LaTocha, Dorian H., Johnson, Kara J., You, Huihong, Luo, Jenny, Riddle, Steven M., Marks, Bryan D., Vogel, Kurt W., Koop, Dennis R., Apgar, John, Tyner, Jeffrey W., Deininger, Michael W., Druker, Brian J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3674150/
https://ncbi.nlm.nih.gov/pubmed/23576564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-12-3904
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados